CLINICAL REVIEW

WILEY

Transoral endoscopic thyroidectomy vestibular approach vs conventional open thyroidectomy: Meta-analysis

Yichao Wang MD^1 | Shengliang Zhou MD^2 | Xueting Liu MD^3 | Shu Rui MA^1 | Zhihui Li MD^1 | Jingqiang Zhu MD^1 | Tao Wei MD^1

¹Department of Thyroid, Parathyroid Surgery Center, West China Hospital, Sichuan University, Chengdu, China

²West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China

³Department of Evidence-Based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, China

Correspondence

Tao Wei, MD, Department of Thyroid, Parathyroid Surgery Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China. Email: taoweiweitaowt@163.com

Funding information

Sichuan Science and Technology Program, Grant/Award Number: 2019YJ0038

Abstract

Background: To conduct a meta-analysis to compare the safety and efficacy of transoral endoscopic thyroidectomy vestibular approach (TOETVA) with conventional open thyroidectomy (COT).

Methods: MEDLINE, EMBASE, Science Citation Index Expanded, and the Cochrane Central Register of Controlled Trials in the Cochrane Library from January 2007 to March 2020 were searched to identify studies comparing TOETVA and COT.

Results: Six eligible nonrandomized studies involving 1151 patients were included. Meta-analysis results revealed that TOETVA group had a significantly longer operative time (weighted mean difference [WMD], 66.09; 95% confidence interval [CI], 35.22-96.96; P < .0001) and larger amount of drainage (WMD, 98; 95% CI, 20.14-175.86; P = .01). There were no significant differences in terms of postoperative outcomes.

Conclusion: TOETVA appears to be as feasible and safe as the COT for the treatment of patients with benign thyroid nodules and selected differential thyroid carcinomas.

K E Y W O R D S

COT, meta-analysis, minimally invasive surgery, TOETVA

1 | INTRODUCTION

Conventional open thyroidectomy (COT) has traditionally been accepted as the standard surgery for some thyroid diseases. Due to the noticeable scar on the anterior neck caused by COT and increasingly cosmetic requirements,^{1,2} especially in women, a variety of endoscopic thyroidectomy (ET) approaches have been developed, such as subclavian,³ areola,⁴ breast,⁵ axillary,⁶ axillo-breast,⁷ and dorsal approach.⁸ However, concerns were also raised as these approaches may associate with an extensive flap dissection, scar hyperplasia at the incision sites, and difficulties in dissecting the lower part of central lymph node.^{9,10} Along with the emergence of natural orifice transluminal endoscopic surgery (NOTES) and development of endoscopic instruments, transoral endoscopic thyroidectomy vestibular approach (TOETVA) has been rapidly developed for patients with benign thyroid nodules and selected differential thyroid carcinomas.¹¹ TOETVA is considered as a minimally invasive surgery with no cutaneous scar and shorter tissue dissection.^{9,11}

Recently, increasing evidence has investigated the safety and feasibility of the TOETVA with a paucity of comparative studies.⁹⁻¹³ Although a few studies have directly compared TOETVA and COT,¹⁴⁻²⁰ it has failed to reach a consensus whether TOETVA is safe and feasible for thyroid lesions because of small number of sample

346 WILEY-

WANG ET AL.

size and assessment at a single institution. Up to the present, no meta-analysis has systematically reviewed the differences between TOETVA and COT. We therefore sought to conduct a meta-analysis to compare the intraoperative outcomes and postoperative complications of patients undergoing TOETVA and COT.

2 | PATIENTS AND METHODS

2.1 | Systematic literature search

A systematic literature search of EMBASE, MEDLINE, the Cochrane Central Register of Controlled Trials in the Cochrane Library and Science Citation Index Expanded between January 2007 and March 2020 was performed for comparing TOETVA and COT. Medical subject headings and key words were as follows: "endoscopy" and "transoral endoscopic" and "vestibular" and "thyroidectomy" or "thyroid surgery." Only human studies published in English language with full-text descriptions were considered in the analysis. Relevant studies were also identified from the reference lists of the previous articles and reviews. Final inclusion of articles was determined by consensus from two independent reviewers, when this failed, a third author was adjudicated.

2.2 | Inclusion and exclusion criteria

Two reviewers independently scanned and identified the search findings for eligible studies. Inclusion criteria for eligibility were as follows: (a) studies reported in English language; (b) clear documentation of comparison between the TOETVA and COT; (c) studies that reported on at least one of the outcomes mentioned below; (d) multiple studies were published by the same institution and/or authors, either the higher quality study or the most recent publication was included. Studies were excluded from the analysis based on the following: (a) abstracts, reviews, case reports, letters, editorials, expert opinions; (b) studies without control groups; (c) absence of clearly reported outcomes of interest.

2.3 | Outcomes of interest

Intraoperative and postoperative outcomes were evaluated to compare TOETVA and COT. Operative time and blood loss were the main intraoperative outcomes. Postoperative outcomes included transient recurrent laryngeal nerve (RLN) palsy, permanent RLN palsy, transient hypocalcaemia, permanent hypocalcaemia, number of retrieved central lymph node, number of metastatic central lymph nodes, postoperative hospital stay, hematoma, and wound infection.

2.4 | Data extraction and quality assessment

Two independent reviewers extracted the data from eligible studies using standardized forms. Data extracted from the selected study included: population characteristics, operative details, and postoperative outcomes. The quality of each study was evaluated using the Newcastle-Ottawa Scale with some modifications. Studies were considered as higher quality if the quality achieves six or more stars.²¹

2.5 | Statistical analysis


Meta-analysis was carried out using Review Manager software, version 5.0 (The Cochrane Collaboration, Oxford, UK). Continuous variables were performed with weighted mean difference (WMD) with corresponding 95% confidence interval (CI), whereas categorical variables were analyzed using odds ratio (OR) with corresponding 95% CI. Medians were converted to means using a previously described methodology.²² Pooled outcome measures were calculated using fixed or random effects model, depending on the heterogeneity. Heterogeneity was assessed using chi-square test, with a *P* value of <.1 indicating significant; I^2 values were estimated for the extent of heterogeneity. ²³ If the test yielded an I^2 value of >50%, the random effects analysis was performed. In addition, sensitivity analyses were conducted by excluding individual studies from the data set to analyze their relative effect on the overall pooled estimates.

3 | RESULTS

3.1 | Study characteristics

There were 187 articles relevant to the search strategy. Fourteen articles were selected for further investigation. Of these, seven studies were further excluded by a close scrutiny, due to the only comparison with other operation approach, two studies had been published by the same institute and had overlapping patient populations. One study published recently was included. Therefore, six studies¹⁵⁻²⁰ matched the inclusion criteria and were included. All these studies were nonrandomized

FIGURE 1 Flow diagram depicting study selection



controlled trials. A flow chart for selection of articles was shown in Figure 1.

The six articles published between 2017 and 2020 involved a total of 1151 patients: 478 in the TOETVA group and 673 patients in the COT group. The number of patients in the included studies varied from 40 to 432. Three studies were carried out in China, two in Thailand, and one in Mexico. The general characteristics and quality assessments of the studies included in the meta-analysis are summarized in Tables 1 and 2.

3.2 | Intraoperative outcomes

All the results of the analyses are summarized in Table 3. All studies explicitly provided information on operative time. Meta-analysis showed that TOETVA group was associated with a significant increase in the operative time (WMD, 66.09; 95% CI, 35.22-96.96; P < .0001) (Figure 2A). Five studies revealed no statistically significant difference in the blood loss between the two groups (WMD, 0.93; 95% CI, -1.54 to 3.39; P = .46) (Figure 2B).

3.3 | Postoperative outcomes

Two studies reported on amount of drainage between the two groups and showed a larger amount of drainage in the TOETVA group (WMD, 98; 95% CI, 20.14-175.86;

P = .01) (Figure 2C). Three studies revealed no significant difference in the number of retrieved central lymph node between the two groups (OR: 0.29; 95% CI: -1.35 to 1.93, P = .73) (Figure 2D). Furthermore, analysis of the pooled data from two studies revealed that the two groups did not differ significantly in the number of metastatic central lymph nodes (OR: 0.32; 95% CI: -0.00 to 0.65, P = .05) (Figure 2E).

WILEY

347

No significant differences were observed between the two operative methods in terms of transient RLN palsy (OR, 1.01; 95% CI, 0.52-1.93; P = .98) (Figure 2F), permanent RLN palsy (OR, 3.04; 95% CI, 0.12-75.69; P = .50), transient hypocalcaemia (OR, 0.96; 95% CI, 0.56-1.65; P = .89) (Figure 2G), permanent hypocalcaemia (OR, 0.32; 95% CI, 0.01-8.26; P = .49), hematoma (OR, 7.93; 95% CI, 0.97-65.12; P = .05) (Figure 2H), wound infection (OR, 3.15; 95% CI, 0.12-82.16; P = .49), and postoperative hospital stay (WMD, 0.02; 95% CI, -0.50 to 0.54; P = .94).

3.4 | Sensitivity and subgroup analyses

Sensitivity analyses were carried out by excluding each individual study from each outcome measure. These exclusions did not change the overall results of cumulative analyses. Subgroup analyses were conducted according to high-quality studies and studies only including patients with papillary thyroid carcinoma. The results of the analyses were consistent with the previous

TABLE1 G	eneral ch	General characteristics of included studies	of included	studies						
Reference	Year	Country	Design	Group	No. of patients	Age (years)	Male/ female	Matching ^a	Type of procedure	Pathological diagnosis, PTC/BTN
Anuwong et al ¹⁵	2018	Thailand	Rtro	TOETVA COT	216 216	35.1 ± 11.9 35.3 ± 12.1	20/199 19/197	1-4	a = 133, b = 86 a = 132, b = 84	NA NA
Bian et al ¹⁶	2018	China	Rtro	TOETVA COT	30	24.0 (17-41) 26.5 (17-44)	1/29 0/30	1, 4, 10	f = 30 f = 30	30/0 30/0
Pérez-Soto et al ¹⁷	2019	Mexico	Rtro	TOETVA COT	20 20	$48.10 \\ \pm 15.67 \\ 45.55 \\ \pm 14.42$	2/18 34/104	1, 3-7	a = 3, b = 13, c = 2, d = 1, e = 1 a = 3, b = 16, c = 1	18/2 18/2
Wang et al ¹⁸	2019	China	Rtro	TOETVA COT	80 80	31.48 ± 6.60 32.59 ± 5.18	13/179 53/213	1, 2, 4, 8, 9	f = 80 f = 80	80/0 80/0
Sun et al ¹⁹	2020	China	Rtro	TOETVA COT	100 289	29.65 \pm 6.57 45.18 \pm 11.47	14/86 124/165	1, 2, 4, 8	f = 100 f = 289	100/0 289/0
Kasemsiri et al ²⁰	2020	Thailand	Pro	TOETVA COT	32 38	38.3 ± 11.3 46.7 ± 10.9	0/32 4/34	1, 2, 4, 7	a = 32 $a = 38$	1/31 0/38
<i>Note: a</i> : hemithyroi tral neck dissection. Abbreviations: BTN ^a 1 = age; 2 = gendei	roidectom on. TN, benig der; 3 = t	iy; <i>b</i> : total th n thyroid no ype of proced	lyroidectom dule; NA, n dure; 4 = tu	y; c: near tota tot available; tmor size; 5 =	<i>Note: a</i> : hemithyroidectomy; <i>b</i> : total thyroidectomy; <i>c</i> : near total thyroidectomy; <i>d</i> : subtotal thyroidectomy; <i>e</i> : total thyroidectomy plu. tral neck dissection. Abbreviations: BTN, benign thyroid nodule; NA, not available; Pro, prospective; PTC, papillary thyroid carcinoma; Rtro, retrospective. ^a 1 = age; 2 = gender; 3 = type of procedure; 4 = tumor size; 5 = body mass index; 6 = length of stay;7 = pathological diagnosis; 8 = m	<i>d</i> : subtotal thy PTC, papillary :; 6 = length of	roidectomy; <i>e</i> : thyroid carcinc stay;7 = patho	total thyroidect ama; Rtro, retroi logical diagnosi	omy plus central neck dissectic spective. s; 8 = multiplicity 9 = bilateral	<i>Note: a</i> : hemithyroidectomy; <i>b</i> : total thyroidectomy; <i>c</i> : near total thyroidectomy; <i>d</i> : subtotal thyroidectomy; <i>e</i> : total thyroidectomy plus central neck dissection; <i>f</i> : hemithyroidectomy plus central neck dissection. Abbreviations: BTN, benign thyroid nodule; NA, not available; Pro, prospective; PTC, papillary thyroid carcinoma; Rtro, retrospective. ^a 1 = age; 2 = gender; 3 = type of procedure; 4 = tumor size; 5 = body mass index; 6 = length of stay;7 = pathological diagnosis; 8 = multiplicity 9 = bilateral PTC; 10 = T-classification stage.

³⁴⁸ ↓ WILEY-

TABLE 2Newcastle-Ottawascoring system for nonrandomizedcomparative studies

References	Selection star	Comparability star	Outcome star	Total star
Anuwong et al ¹⁵	3	2	1	6
Bian et al ¹⁶	2	2	0	4
Pérez-Soto et al ¹⁷	3	1	0	4
Wang et al ¹⁸	2	2	2	6
Sun et al ¹⁹	3	2	2	7
Kasemsiri et al ²⁰	3	1	2	6

Note: Comparability variables include age, gender, type of procedure, tumor size, multiplicity, and pathological diagnosis.

TABLE 3 Meta-analysis of the subgroups for studies comparing TOETVA and COT

Outcomes	No. of studies	No. of patients	OR/WMD	95% CI	P value	I ² (%)
High-quality studies						
Operative time(min)	4	1051	57.80	22.27, 93.33	.001	98
Blood loss (mL)	3	662	1.38	-1.46, 4.23	.34	0
Transient RLN palsy	4	1051	0.89	0.45, 1.76	.74	0
Permanent RLN palsy	2	592	3.04	0.12, 75.69	.50	-
Tansient hypocalcemia	2	592	1.05	0.58, 1.88	.88	0
No. of retrieved central lymph node	2	549	-0.17	-3.04, 2.70	.91	86
No. of metastatic central lymph nodes	2	549	0.32	-0.00, 0.65	.05	0
Amount of drainage	2	549	98.00	20.14, 175.86	.01	99
Studies only including PTC						
Operative time (min)	3	609	90.44	76.21, 104.67	<.00001	78
Blood loss (mL)	2	220	1.56	-1.25, 4.38	.28	0
Transient RLN palsy	3	609	0.75	0.26, 2.15	.59	0
No. of retrieved central lymph node	3	609	0.29	-1.35, 1.93	.73	73
No. of metastatic central lymph nodes	2	549	0.32	-0.00, 0.65	.05	0
Amount of drainage	2	549	98	20.14, 175.86	.01	99

Abbreviations: CI, confidence intervals; COT, conventional open thyroidectomy; OR, odds ratios; PTC, papillary thyroid carcinoma; RLN, recurrent laryngeal nerve; TOETVA, transoral endoscopic thyroidectomy vestibular approach; WMD, weighted mean differences.

outcomes when all studies were considered. These results are illustrated in Table 3.

3.5 | Publication bias

The funnel plot of the studies based on the transient RLN palsy is shown in Figure 3. A somewhat asymmetric distribution around the vertical axis indicates moderate publication bias. However, the result needs to be interpreted with caution, due to the limited numbers of the included studies.

4 | DISCUSSION

ET is currently considered as an alternative to the COT for thyroid diseases. TOETVA, as a new endoscopic approach, not only caters for the higher esthetic requirement of women, but also provides easy access to the bilateral thyroid and central compartment.¹¹ Since the successful report of TOETVA by Nakajo et al²⁴ and Wang et al²⁵ in 2013, the benefits afforded by TOETVA, such as cutaneous scar-free and minimally invasive surgery,¹¹ have led to its increased application in thyroid surgery. Five published systematic reviews²⁶⁻³⁰have investigated

349

WILEY-

(A)									
(/ ()	Study or Subgroup	TOET Mean		l Mean	COT SD	Total \	Veiaht	Mean Differend IV, Random, 9	
-	Anuwong 2018	100.8 3	9.7 216	5 79.4	32.1	216	17.4%	21.40 [14.59, 2	8.21]
	Bian 2018 Kasemsiri 2020		.63 30 6.3 32		12.99 35.5		17.1% 16.9%	102.00 (90.09, 11 39.70 (25.19, 5	
	Pe'rez-Soto 2019 Sun 2020		2.5 20 1.3 100		49.25 21.88		14.3% 17.3%		
	Wang 2019	193	47 80		49		16.9%	• •	
	Total (95% CI)		478				100.0%	66.09 [35.22, 9	6.96]
	Heterogeneity: Tau ² = Test for overall effect:			8, df = 5	(P < 0.0	0001); I²:	= 98%		-100 -50 0 50 100 Favours TOETVA Favours COT
(D)		TOFT	~					N Diff	
(B)	Study or Subgroup	TOET Mean S	D Total		COT SD	Total W	eight	Mean Difference IV, Fixed, 959	
	Anuwong 2018 Bian 2018	36.9 32 25 9	.4 216 .8 30	37.6 25	23.1 9.8		1.6% 4.7%	-0.70 [-6.01, 4 0.00 [-4.96, 4	
	Kasemsiri 2020 Pe′rez-Soto 2019	23.9 46 38.25 38	.2 32	24.2	29	38	1.8%	-0.30 [-18.77, 18	17]
	Wang 2019	18.65 13.3		16.34	126.6 8.19		0.2% 1.8%	-63.55 [-121.59, -5 2.31 [-1.11, 5	
	Total (95% Cl)		378			384 10	0.0%	0.93 [-1.54, 3	39]
	Heterogeneity: Chi ² = Test for overall effect:			I² = 32%					-20 -10 0 10 20
	restion overall ellect.	2 - 0.74 () -	0.40)						Favours TOETVA Favours COT
(C)	Church and Carlo and	TOETV			сот	Total	4-1-1-4	Mean Difference	
-	Study or Subgroup Sun 2020	Mean 9 175.75 54.	<u>SD Total</u> 21 100	Mean 117.44		Total 1 289	<u>veight</u> 50.0%	IV, Random, 9 58.31 [46.43]	
	Wang 2019	188.85 52	2.7 80	51.09	23.73	80	50.0%	137.76 [125.10, 1	50.42]
	Total (95% Cl) Heterogeneity: Tau ² =	2446.00.01	180	df 4 /D	- 0 000	369 1		98.00 [20.14, 17	(5.86]
	Test for overall effect:			ui = 1 (P	< 0.000	01), 1 9	970		-100 -50 0 50 100 Favours TEOTVA Favours COT
(D)		TOET	1/0		сот			Mean Differenc	
(D)	Study or Subgroup		SD Total			Total V	Veight	IV, Random, 95%	
	Bian 2018 Sun 2020	6.5 3 7 4.1	3.4 30 08 100		3.2 3.71		31.3% 40.6%	1.00 [-0.67, 2. 1.17 [0.26, 2.	
	Wang 2019	8.24 4.					28.1%	-1.77 [-3.71, 0.	
	Total (95% CI)		210			399 1	00.0%	0.29 [-1.35, 1.	93] 🔶
	Heterogeneity: Tau ² Test for overall effect			= 2 (P =	0.02);	²= 73%			-20 -10 0 10 20
			- 0.1 0/						Favours TOETVA Favours COT
(E)		TOET	IVA		сот			Mean Difference	e Mean Difference
	Study or Subaroup	Moan	SD Total	l Moan		Total	Mojah	t B/ Eivad 05%	CI By Eived 05% CI
-	Study or Subgroup Sun 2020	Mean 1.12 1.	<u>SD Tota</u> .62 100		SD	Total 289	<u>Neight</u> 77.6%	t IV, Fixed, 95% 0.30 (-0.07, 0.6	
-			.62 100	0.82	SD			6 0.30 [-0.07, 0.6	7]
-	Sun 2020 Wang 2019 Total (95% Cl)	1.12 1. 1.48 2.	.62 100 .42 80 180) 0.82) 1.08	SD 1.63 1.99	289 80	77.6% 22.4%	6 0.30 [-0.07, 0.6	7]
-	Sun 2020 Wang 2019	1.12 1. 1.48 2. = 0.06, df = 1	.62 100 .42 80 180 I (P = 0.80) 0.82) 1.08	SD 1.63 1.99	289 80	77.6% 22.4%	6 0.30 [-0.07, 0.6 6 0.40 [-0.29, 1.0	$\begin{bmatrix} 7 \\ 9 \end{bmatrix} \\ \hline \\ -4 \\ -4 \\ -2 \\ 0 \\ 2 \\ 4 \\ -2 \\ -2 \\ -2 \\ -2 \\ -2 \\ -2 \\$
(E)	Sun 2020 Wang 2019 Total (95% CI) Heterogeneity: Chi ² :	1.12 1. 1.48 2. = 0.06, df = 1 t: Z = 1.94 (F	.62 100 .42 80 180 I (P = 0.80 P = 0.05)) 0.82) 1.08) 0); I ² = 0	<u>SD</u> 1.63 1.99 %	289 80	77.6% 22.4% 100.0%	5 0.30 [-0.07, 0.6 5 0.40 [-0.29, 1.0 5 0.32 [-0.00, 0.6	7] 9]
(F)	Sun 2020 Wang 2019 Total (95% CI) Heterogeneity: Chi ² :	1.12 1. 1.48 2. = 0.06, df = 1 t: Z = 1.94 (F TOET	.62 100 .42 80 180 I (P = 0.80 P = 0.05)	0 0.82 0 1.08 0); l ² = 0 CO1	SD 1.63 1.99 %	289 80 369	77.6% 22.4% 100.0%	6 0.30 [-0.07, 0.6 6 0.40 [-0.29, 1.0	$\begin{bmatrix} 7 \\ 9 \end{bmatrix} \\ \hline \\ -4 \\ -4 \\ -2 \\ 0 \\ 2 \\ 4 \\ -2 \\ -2 \\ -2 \\ -2 \\ -2 \\ -2 \\$
(F)	Sun 2020 Wang 2019 Total (95% Cl) Heterogeneity: Chi ² : Test for overall effec <u>Study or Subgroup</u> Anuwong 2018	1.12 1. 1.48 2. = 0.06, df = 1 t: Z = 1.94 (F TOET <u>Events</u> 9	62 100 42 80 180 1 (P = 0.80 2 = 0.05) VA <u>Total 1</u> 216	0 0.82 0 1.08 0); I ² = 0 0); I ² = 0 <u>CO1</u> <u>Events</u> 9	SD 1.63 1.99 % <u>Total</u> 216	289 80 369	77.6% 22.4% 100.0% C t <u>M-H</u>	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.34 Ratio 1, Fixed, 95% C1 .00 [0.39, 2.57] 	7] 9] -4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio
(F)	Sun 2020 Wang 2019 Total (95% CI) Heterogeneity: Chi ² : Test for overall effec <u>Study or Subgroup</u>	1.12 1. 1.48 2. = 0.06, df = 1 t: Z = 1.94 (F TOET	62 100 42 80 180 1 (P = 0.80 2 = 0.05) VA Total 1	0 0.82 0 1.08 0 0); I ² = 0 0); I ² = 0 COT Events	SD 1.63 1.99 %	289 80 369 Weigh	77.6% 22.4% 100.0% <u>C</u> t <u>M-H</u> 5 1	 0.30 (-0.07, 0.6 0.40 (-0.29, 1.0 0.32 (-0.00, 0.6 Ddds Ratio 4, Fixed, 95% Cl 	7] 9] -4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio
(F)	Sun 2020 Wang 2019 Total (95% Cl) Heterogeneity: Chi [#] : Test for overall effect Study or Subgroup Anuwong 2018 Bian 2018 Kasemsiri 2020 Pe´rez-Soto 2019	1.12 1. 1.48 2. = 0.06, df = 1 t: Z = 1.94 (F TOET <u>Fivents</u> 9 0 1 2	62 100 42 80 1 (P = 0.84 P = 0.05) VA <u>Total 1</u> 216 30 32 20) 0.82) 1.08) 0); I ² = 0 0); I ² = 0 0 E <u>vents</u> 9 0 1 0	SD 1.63 1.99 % <u>Total</u> 216 30 38 20	289 80 369 <u>Weigh</u> 47.89 4.99 2.49	77.6% 22.4% 100.0% <u>C</u> t <u>M-H</u> 5 1.4 5 5.54	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.040 Ratio 4, Fixed, 95% CI 0.00 [0.39, 2.57] Not estimable 19 [0.07, 19.88] 4 [0.25, 123.08] 	7] 9] -4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio
(F)	Sun 2020 Wang 2019 Total (95% Cl) Heterogeneity: Chi [#] : Test for overall effec Study or Subgroup Anuwong 2018 Bian 2018 Kasemsiri 2020	1.12 1. 1.48 2. = 0.06, df = 1 t: Z = 1.94 (F TOET <u>TOET</u> 9 0 1	62 100 42 80 180 ((P = 0.80 ? = 0.05) VA <u>Total 1</u> 216 30 32) 0.82) 1.08)); ² = 0); ² = 0 <u>CO1</u> <u>Events</u> 9 0 1	SD 1.63 1.99 % <u>Total</u> 216 30 38	289 80 369 <u>Weigh</u> 47.89	77.6% 22.4% 100.0% t <u>M-H</u> 5 1.1 5 5.54 6 0	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.45 Ratio 4, Fixed, 95% CI .00 [0.39, 2.57] Not estimable 19 [0.07, 19.88] 	7] 9] -4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio
(F)	Sun 2020 Wang 2019 Total (95% CI) Heterogeneity: Chi ^r : Test for overall effect Study or Subgroup Anuwong 2018 Bian 2018 Kasemsiri 2020 Pe'rez-Soto 2019 Sun 2020	1.12 1. 1.48 2. = 0.06, df = 1 t: Z = 1.94 (F TOET <u>Events</u> 9 0 1 2 1 2 1	62 100 42 80 (P=0.84 >=0.05) VA <u>Total 1</u> 216 30 32 20 100 80) 0.82) 1.08) 0); I ² = 0 (); I ² = 0 ()	 SD 1.63 1.99 % <u>Total</u> 216 30 38 20 289 80 	289 80 369 Weigh 47.89 4.99 2.49 8.59 36.49	77.6% 22.4% 100.0% t <u>M-H</u> 5 1.* 5 5.54 5 0 5 0	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.32 [-0.00, 0.6 0.00 [0.39, 2.57] Not estimable 19 [0.07, 19.88] 4 [0.25, 123.08] 0.96 [0.10, 9.36] 0.70 [0.21, 2.29] 	7] 9] -4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio
(F)	Sun 2020 Wang 2019 Total (95% Cl) Heterogeneity: Chi [#] : Test for overall effect Study or Subgroup Anuwong 2018 Bian 2018 Kasemsiri 2020 Pe'rez-Soto 2019 Sun 2020 Wang 2019 Total (95% Cl) Total events	1.12 1. 1.48 2. = 0.06, df = 1 t Z = 1.94 (F TOET 9 0 1 2 1 5 18	62 100 42 80 180 1 (P = 0.81 ≥ = 0.05) VA Total 1 216 30 32 20 100 80 478	0 0.82 0 1.08 0); ² = 0 0); ² = 0 COI Events 9 0 1 0 3 7 20	50 1.63 1.99 5 Total 216 30 38 20 289 80 673	289 80 369 Weigh 47.89 4.99 2.49 8.59	77.6% 22.4% 100.0% t <u>M-H</u> 5 1.* 5 5.54 5 0 5 0	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.04 [-0.39, 2.57] Not estimable 19 [0.07, 19.88] 4 [0.25, 123.08] 0.96 [0.10, 9.36] 	7] 9] -4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio
(F)	Sun 2020 Wang 2019 Total (95% CI) Heterogeneily: Chi [#] : Test for overall effect Study or Subgroup Anuwong 2018 Bian 2018 Kasemsiri 2020 Pe*rez-Soto 2019 Sun 2020 Wang 2019 Total (95% CI)	1.12 1. 1.48 2. = 0.06, df = 1 t: Z = 1.94 (F TOET Events 9 0 1 2 1 5 2 18 2 = 1.55, df =	62 100 42 80 180 1 (P = 0.81 2 = 0.05) VA Total 1 216 30 32 20 100 80 478 = 4 (P = 0	0 0.82 0 1.08 0 0); ² = 0 COI Events 9 0 1 0 3 7 20 1.82); ² =	50 1.63 1.99 5 Total 216 30 38 20 289 80 673	289 80 369 Weigh 47.89 4.99 2.49 8.59 36.49	77.6% 22.4% 100.0% t <u>M-H</u> 5 1.* 5 5.54 5 0 5 0	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.32 [-0.00, 0.6 0.00 [0.39, 2.57] Not estimable 19 [0.07, 19.88] 4 [0.25, 123.08] 0.96 [0.10, 9.36] 0.70 [0.21, 2.29] 	7] 9] -4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio M-H, Fixed, 95% Cl
	Sun 2020 Wang 2019 Total (95% CI) Heterogeneity: Chi ² : Test for overall effect Study or Subgroups Anuwong 2018 Bian 2018 Kasemsiri 2020 Pe'rez-Soto 2019 Sun 2020 Wang 2019 Total (95% CI) Total events Heterogeneity: Chi ²	1.12 1. 1.48 2. = 0.06, df = 1 t: Z = 1.94 (F TOET Events 9 0 1 2 1 5 2 18 2 = 1.55, df =	62 100 42 80 180 1 (P = 0.81 2 = 0.05) VA Total 1 216 30 32 20 100 80 478 = 4 (P = 0	0 0.82 0 1.08 0 0); ² = 0 COI Events 9 0 1 0 3 7 20 1.82); ² =	50 1.63 1.99 5 Total 216 30 38 20 289 80 673	289 80 369 Weigh 47.89 4.99 2.49 8.59 36.49	77.6% 22.4% 100.0% t <u>M-H</u> 5 1.* 5 5.54 5 0 5 0	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.32 [-0.00, 0.6 0.00 [0.39, 2.57] Not estimable 19 [0.07, 19.88] 4 [0.25, 123.08] 0.96 [0.10, 9.36] 0.70 [0.21, 2.29] 	7] 9] -4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio M-H, Fixed, 95% CI
(F)	Sun 2020 Wang 2019 Total (95% CI) Heterogeneity: Chi ² : Test for overall effect Study or Subgroup Anuwong 2018 Bian 2018 Kasemsiri 2020 Pe'rez-Soto 2019 Sun 2020 Wang 2019 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effe	1.12 1. 1.48 2. = 0.06, df = 1 t: Z = 1.94 (F TOET <u>Fevents</u> 9 0 1 2 1 5 * = 1.55, df = ct: Z = 0.02 TOET	$\begin{array}{cccc} 62 & 100 \\ 42 & 80 \\ 1 (P = 0.81 \\ P = 0.05) \\ \hline VA \\ \hline Total 1 \\ 216 \\ 30 \\ 32 \\ 20 \\ 100 \\ 80 \\ 478 \\ = 4 (P = 0 \\ (P = 0.98 \\ VA \\ \end{array}$	0) 0.82 0) 1.08 0); ² = 0 0); ² = 0 0 1 0 1 0 3 7 7 20 3.82); ² = 0) CO1	SD 1.63 1.99 % 7 7 7 7 7 7 7 7 7 7 7 7 8 0 80 80 80 673 80 673 80	289 80 369 47.89 4.99 2.49 8.59 36.49 100.05	77.6% 22.4% 100.0% 5 1.4 5 1.4 5 5.5 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.32 [-0.00, 0.6 0.00 [0.39, 2.57] Not estimable 19 [0.07, 19.88] 4 [0.25, 123.08] 0.60 [0.21, 2.29] 0.01 [0.52, 1.93] Ddds Ratio 	7] 9] 5] -4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio M-H, Fixed, 95% CI 0.01 0.1 1 10 100 Favours TOETVA Favours COT Odds Ratio
	Sun 2020 Wang 2019 Total (95% Cl) Heterogeneity: Chi [#] - Test for overall effect Study or Subgroup Anuwong 2018 Bian 2018 Kasemsiri 2020 Pe'rez-Soto 2019 Sun 2020 Wang 2019 Total (95% Cl) Total events Heterogeneity: Chi [#] Test for overall effect	1.12 1. 1.48 2. = 0.06, df = 1 t: Z = 1.94 (F TOET TOET 5 0 1 2 1 5 1 8 ² = 1.55, df = ct: Z = 0.02 TOET <u>Events</u>	62 100 42 80 $1 (P = 0.81)^2 = 0.05)^2$ 216 30 32 2016 30 300 32 200 100 100 80 478 478 478 $4(P = 0.98)^2$ VA VA $Total = 1$ $Total = 1$) 0.822) 1.08)))); ² = 0)); ² = 0 COT Events 9 0 1 1 0 3 7 7 20 82); ² =)) COT Events	SD 1.63 1.99 % 7 7 7 7 7 7 8 8 8 7 7 8 8 8 7 7 8	289 80 369 4.99 2.49 8.59 36.49 100.03	77.6% 22.4% 100.0% 5 1.4 5 1.4 5 5.5 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.32 [-0.00, 0.6 0.00 [0.39, 2.57] Not estimable 19 [0.07, 19.88] 4 [0.25, 123.08] 0.96 [0.10, 9.36] 0.70 [0.21, 2.29] .01 [0.52, 1.93] Ddds Ratio 4, Fixed, 95% CI 	7] 9] -4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio M-H, Fixed, 95% Cl 0.01 0.1 1 0 100 Favours TOETVA Favours COT
	Sun 2020 Wang 2019 Total (95% CI) Heterogeneity: Chi [#] : Test for overall effect Study or Subgroup Anuwong 2018 Bian 2018 Kasemsiri 2020 Pe'rez-Soto 2019 Sun 2020 Wang 2019 Total (95% CI) Total events Heterogeneity: Chi [#] Test for overall effe Study or Subgroup Anuwong 2018 Pe'rez-Soto 2019	1.12 1. 1.48 2. = 0.06, df = 1 t: Z = 1.94 (F TOET DEvents 9 0 1 2 1 5 * = 1.55, df = 1 8 * = 1.55, df = 1 5 * = 1.55, df = 1 5 * Z = 0.02 TOET 1 5 * Z = 0.02 1 5 * Z = 0.02 5 * Z = 0.02 5 * Z = 0.02 5 * Z = 0.02 * Z	62 100 42 80 $1 (P = 0.81)^2$ 90.05 VA Total I 2166 30 32 20 100 80 478 $4 (P = 0)$ $(P = 0.98)$ VA Total I 216 20 2010 478 $4 (P = 0)$ $216 20$ 2016) 0.822) 1.08) 1.08)); ² = 0 (0); ² = 0 (0); ² = 0 1 0 1 0 1 0 1 0 3 7 20 0 20 1 20 20 (²); ² = 0 20 20 20 20 20 20 20 20 20 20 20 20 20	SD 1.63 1.63 216 300 289 80 673 = 0%	289 80 369 4.99 2.49 36.49 100.09 100.09 Weight 66.19 19.49	77.6% 22.4% 100.0% C C C C C C C C C C C C C C C C C C C	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.32 [-0.00, 0.6 0.45 Ratio 4. Fixed, 95% C1 0.00 [0.39, 2.57] Not estimable 19 [0.07, 19.88] 4 [0.25, 123.08] 0.96 [0.10, 9.36] 0.70 [0.21, 2.29] .01 [0.52, 1.93] Odds Ratio 4. Fixed, 95% C1 .17 [0.62, 2.20] 0.62 [0.16, 2.43] 	7] 9] 5] -4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio M-H, Fixed, 95% CI 0.01 0.1 1 10 100 Favours TOETVA Favours COT Odds Ratio
	Sun 2020 Wang 2019 Total (95% Cl) Heterogeneity: Chi [#] - Test for overall effect Study or Subgroup Anuwong 2018 Bian 2018 Kasemsiri 2020 Pe*rez-Soto 2019 Sun 2020 Wang 2019 Total (95% Cl) Total events Heterogeneity: Chi [#] Test for overall effe Study or Subgroup Anuwong 2018	1.12 1. 1.48 2. = 0.06, df = 1 t: Z = 1.94 (F TOET <u>TOET</u> 1 2 9 0 0 1 2 1 5 * = 1.55, df = 1.55, df = t: Z = 0.02 TOET <u>TOET</u> 23	62 100 42 80 $1 (P = 0.81)^2$ 90.05 VA Total I 2166 30 32 20 100 80 478 $4 (P = 0)$ $(P = 0.98)$ VA Total I 216 20 2010 478 $4 (P = 0)$ $216 20$ 2016) 0.822) 1.08)))); ² = 0 (); ² = 0 () () () () () () () () () () () () ()	SD 1.63 1.99 % 7 70tal 216 30 38 20 289 80 673 673 = 0%	289 80 369 47.89 4.99 2.49 8.59 36.49 100.0 9 100.0 9	77.6% 22.4% 100.0% C C C C C C C C C C C C C C C C C C C	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.32 [-0.00, 0.6 0.45 Ratio 4. Fixed, 95% CI .00 [0.39, 2.57] Not estimable 19 [0.07, 19.88] 4 [0.25, 123.08] 0.96 [0.10, 9.36] .70 [0.21, 2.29] .01 [0.52, 1.93] Odds Ratio 4. Fixed, 95% CI .17 [0.62, 2.20] 	7] 9] 5] -4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio M-H, Fixed, 95% CI 0.01 0.1 1 10 100 Favours TOETVA Favours COT Odds Ratio
	Sun 2020 Wang 2019 Total (95% Cl) Heterogeneity: Chi ² : Test for overall effect Study or Subgroups Anuwong 2018 Kasemsiri 2020 Pe'rez-Soto 2019 Sun 2020 Wang 2019 Total (95% Cl) Total events Heterogeneity: Chi ⁷ Test for overall effect Study or Subgroups Anuwong 2018 Pe'rez-Soto 2019 Wang 2019 Total (95% Cl)	1.12 1. 1.48 2. = 0.06, df = 1 t: Z = 1.94 (F TOET TOET Puents 0 0 1 2 1 5 - 18 - 18 - - - - - - - - - - - - -	62 100 42 80 $1 (P = 0.81)^2$ 90.05 VA Total I 2166 30 32 20 100 80 478 $4 (P = 0)$ $(P = 0.98)$ VA Total I 216 20 2010 478 $4 (P = 0)$ $216 20$ 2016) 0.822) 1.08)))); ² = 0)); ² = 0 COT <u>Events</u> 20 20 (COT <u>Events</u> 20 7 4	SD 1.63 1.63 1.99 % 7 7 7 7 80 80 673 80 673 80 673 80 7 7 10tal 216 20 80 80	289 80 369 4.99 2.49 36.49 100.09 100.09 Weight 66.19 19.49	77.6% 22.4% 100.0% C t <u>M.H</u> 5 1.4 5 5.54 5 5.54 5 0 5 0 5 0 5 0 6 1.4 6 1 6 1 6 0 6 0 6 0	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.32 [-0.00, 0.6 0.45 Ratio 4. Fixed, 95% C1 0.00 [0.39, 2.57] Not estimable 19 [0.07, 19.88] 4 [0.25, 123.08] 0.96 [0.10, 9.36] 0.70 [0.21, 2.29] .01 [0.52, 1.93] Odds Ratio 4. Fixed, 95% C1 .17 [0.62, 2.20] 0.62 [0.16, 2.43] 	7] 9] 5] -4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio M-H, Fixed, 95% CI 0.01 0.1 1 10 100 Favours TOETVA Favours COT Odds Ratio
	Sun 2020 Wang 2019 Total (95% Cl) Heterogeneity: Chi ² : Test for overall effect Study or Subgroup Anuwong 2018 Kasemsiri 2020 Pe'rez-Soto 2019 Sun 2020 Wang 2019 Total (95% Cl) Total events Heterogeneity: Chi ⁷ Test for overall effe Study or Subgroup Anuwong 2018 Pe'rez-Soto 2019 Wang 2019	1.12 1. 1.48 2. = 0.06, df = 1 t: Z = 1.94 (F TOET Events 0 0 0 1 2 1 5 3 1 1 5 3 1 1 5 5 1 1 1 2 1 5 5 1 1 5 1 1 5 2 3 3 3 3 3 3 3 3 3 3 3 3 1 3 1 1 1 1 1 1 1 1 1 1 1 1 1	62 100 42 80 $1 (P = 0.81)^2 = 0.05)^2$ $20 = 0.05)^2$ VA 216 $20 = 0.00^2$ $30 = 32^2$ 100 80 478 $60^2 (P = 0.98)^2$ VA Total I 216 20 $30 = 32^2$ 20^2 100 80^2 478 $60^2 (P = 0.98)^2$ 478 80^2 478 $80^2 (P = 0.98)^2$ 478 $80^2 (P = 0.98)^2$ $50^2 (P = 0.98)^2$ $50^2 (P = 0.98)^2$ $50^2 (P = 0.98)^2$ $80^2 (P = 0.98)^2$ $50^2 (P = 0.98)^2$ $80^2 (P = 0.98)^2$ $50^2 (P = 0.98)^2$ $80^2 (P = 0.98)^2$ $50^2 (P = 0.98)^2 (P = 0.98)^2$ $80^2 (P = 0.98)^2$ $50^2 (P = 0.98)^2 (P = 0.98)^2$ $80^2 (P = 0.98)^2$ $50^2 (P = 0.98)^2 (P = 0.98)^2 (P = 0.98)^2$ $80^2 (P = 0.98)^2$ $50^2 (P = 0.98)^2 (P = 0.98)^2 (P = 0.98)^2$ $80^2 (P = 0.98)^2$ $50^2 (P = 0.98)^2 (P = 0.98)^2 (P = 0.98)^2$ $80^2 (P = 0.98)^2$ $50^2 (P = 0$) 0.822) 1.08) 1.08) 1.08 0); ² = 0 COT <u>Events</u> 20 3 7 20 8.82); ² = 3 ;) COT <u>Events</u> 20 7 4	SD 1.63 1.99 % 7 7 7 7 7 80 80 6 7 3 80 6 7 3 80 6 7 3 80 7 2 80 80 7 316	289 80 369 4.99 2.49 8.59 36.49 100.05 100.05 Weigh 66.19 19.49 14.49	77.6% 22.4% 100.0% C t <u>M.H</u> 5 1.4 5 5.54 5 5.54 5 0 5 0 5 0 5 0 6 1.4 6 1 6 1 6 0 6 0 6 0	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.32 [-0.00, 0.6 0.00 [0.39, 2.57] Not estimable 19 [0.07, 19.88] 4 [0.25, 123.08] 0.60 [0.21, 2.29] 0.10 [0.52, 1.93] 0.01 [0.52, 1.93] 0.04ds Ratio 1.17 [0.62, 2.20] 0.62 [0.16, 2.43] 0.49 [0.09, 2.74] 	7] 9] -4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio M-H, Fixed, 95% CI
	Sun 2020 Wang 2019 Total (95% Cl) Heterogeneity: Chi [#] - Test for overall effect Study or Subgroup Anuwong 2018 Bian 2018 Kasemsiri 2020 Pe'rez-Soto 2019 Sun 2020 Wang 2019 Total (95% Cl) Total events Heterogeneity: Chi [#] Test for overall effe Study or Subgroup Anuwong 2018 Pe'rez-Soto 2019 Wang 2019 Total (95% Cl) Total events	1.12 1. 1.48 2. = 0.06, df = 1 t. Z = 1.94 (F TOET Events 9 0 0 1 1 2 2 1 5 * = 1.55, df = 1.55, df = t. Z = 0.02 TOET Events 5 2 30 * = 1.36, df =	62 100 42 80 $1 (P = 0.81)^2 = 0.05)^2$ $20 = 0.05)^2$ VA Total I 216 30 32 20 100 80 478 478 = 4 (P = 0 (P = 0.98) VA Total I 216 20 316 = 2 (P = 0 316) 0.822) 1.08)) 1.08)) 1.08)) 1.08)) 1.09 0 0 1 1 0 3 7 20 0 1 0 1 0 3 7 20 0 20 1 20 20 20 7 4 31 1.51); ² =0	SD 1.63 1.99 % 7 7 7 7 7 80 80 6 7 3 80 6 7 3 80 6 7 3 80 7 2 80 80 7 316	289 80 369 4.99 2.49 8.59 36.49 100.05 100.05 Weigh 66.19 19.49 14.49	77.6% 22.4% 100.0% C t <u>M.H</u> 5 1.4 5 5.54 5 5.54 5 0 5 0 5 0 5 0 6 1.4 6 1 6 1 6 0 6 0 6 0	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.32 [-0.00, 0.6 0.00 [0.39, 2.57] Not estimable 19 [0.07, 19.88] 4 [0.25, 123.08] 0.60 [0.21, 2.29] 0.10 [0.52, 1.93] 0.01 [0.52, 1.93] 0.04ds Ratio 1.17 [0.62, 2.20] 0.62 [0.16, 2.43] 0.49 [0.09, 2.74] 	7] 9] 5] -4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio M-H, Fixed, 95% CI 0.01 0.1 1 10 100 Favours TOETVA Favours COT Odds Ratio
(G)	Sun 2020 Wang 2019 Total (95% CI) Heterogeneity: Chi [#] : Test for overall effect Study or Subgroup Anuwong 2018 Bian 2018 Kasemsiri 2020 Pe'rez-Soto 2019 Sun 2020 Wang 2019 Total (95% CI) Total events Heterogeneity: Chi [#] Test for overall effe Study or Subgroup Anuwong 2018 Pe'rez-Soto 2019 Wang 2019 Total (95% CI) Total events Heterogeneity: Chi [#]	1.12 1. 1.48 2. = 0.06, df = 1 t: Z = 1.94 (F TOET Events 0 0 0 1 2 1 5 1 8 = 1.55, df = 1 Events 23 5 2 30 $2^2 = 1.36, df = 1$	62 100 42 80 $1 (P = 0.81)^2 = 0.05)^2$ 216 216 30 216 30 32 20 100 80 478 60 478 700 478 700 478 700 478 700 478 700 478 700 478 700 478 700 80 700 100 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800) 0.822) 1.08) 1.08)); ² = 0 CO1 <u>Events</u> 9 0 1 1 0 3 7 20 0 8.82); ² = 20 7 20 0 8.82); ² = 3 7 20 0 3 3 7 20 0 3 3 7 4 3 3 1 1 5 5 1); ² = 0	<u>SD</u> 1.63 1.99 % <u>Total</u> 216 300 289 80 673 e 0% <u>Total</u> 216 20 80 289 80 673 219 219 80 673 216 20% 316	289 80 369 4.99 2.49 8.59 36.49 100.05 100.05 Weigh 66.19 19.49 14.49	77.6% 22.4% 100.0% C t <u>M.H</u> 5 1.4 5 5.54 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.32 [-0.00, 0.6 0.45 Ratio 4. Fixed, 95% Cl .00 [0.39, 2.57] Not estimable 19 [0.07, 19.88] 4 [0.25, 123.08] .96 [0.10, 9.36] .70 [0.21, 2.29] .01 [0.52, 1.93] .04 [0.52, 1.93] .052 [0.16, 2.43] .49 [0.09, 2.74] .96 [0.56, 1.65] 	7] 9] 5] 4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio M.H. Fixed, 95% CI 0.01 0.1 1 0 100 Favours TOETVA Favours COT Odds Ratio M.H. Fixed, 95% CI 0.01 0.1 1 0 100 Favours TEOTVA Favours COT
	Sun 2020 Wang 2019 Total (95% CI) Heterogeneity: Chi ² : Test for overall effec Study or Subgroug Anuwong 2018 Bian 2018 Kasemsiri 2020 Pe'rez-Soto 2019 Sun 2020 Wang 2019 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effe Study or Subgroug Anuwong 2018 Pe'rez-Soto 2019 Wang 2019 Total (95% CI) Total events Heterogeneity: Chi ² Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effe	1.12 1. 1.48 2. = 0.06, df = 1 t Z = 1.94 (F TOET Events 3 - 1.55, df = 1.55, df = ct Z = 0.02 TOET - Events - 23 - 5 - 2 - 30 - 2 - 0.14 TOET	$\begin{array}{cccc} 62 & 100 \\ 42 & 80 \\ 1 & (P = 0.81 \\ 2 = 0.05) \\ \hline VA \\ \hline Total & 1 \\ 216 \\ 30 \\ 32 \\ 20 \\ 100 \\ 80 \\ \hline 478 \\ \hline 20 \\ 80 \\ \hline 316 $) 0.822) 1.08) 0.822 () 1.08 () 0.9 () 1 () 1	<u>SD</u> 1.63 1.99 % <u>Total</u> 216 30 320 289 80 673 = 0% <u>Total</u> 216 20 80 316 = 0%	289 80 369 4.99 2.49 8.59 36.49 100.09 100.09 14.49 14.49	77.6% 22.4% 100.0% C C C C M.H 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 6 0 5 7 6 7 7 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.32 [-0.00, 0.6 0.01 [0.39, 2.57] Not estimable 19 [0.07, 19.88] 0.96 [0.10, 9.36] 0.70 [0.21, 2.29] 0.01 [0.52, 1.93] 0.04 [0.52, 1.93] 0.17 [0.62, 2.20] 0.25 [0.16, 2.43] 0.49 [0.09, 2.74] .96 [0.56, 1.65] 00dds Ratio 	7] 9] 5] -4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio M.H. Fixed, 95% CI 0.01 0.1 1 10 100 Favours TOETVA Favours COT Odds Ratio M.H. Fixed, 95% CI 0.01 0.1 1 0 100 Favours TOETVA Favours COT Odds Ratio M.H. Fixed, 95% CI 0.01 0.1 1 0 100 Favours TEOTVA Favours COT Odds Ratio
(G)	Sun 2020 Wang 2019 Total (95% Cl) Heterogeneity: Chi ² : Test for overall effect Study or Subgroups Anuwong 2018 Kasemsiri 2020 Pe'rez-Soto 2019 Sun 2020 Wang 2019 Total (95% Cl) Total events Heterogeneity: Chi ⁷ Test for overall effe Study or Subgroups Heterogeneity: Chi ⁷ Total (95% Cl) Total events Heterogeneity: Chi ⁷ Test for overall effe Study or Subgroups	1.12 1. 1.48 2. = 0.06, df = 1 t Z = 1.94 (F TOET Events 0 1 2 1 5 1 8 = 1.55, df = 1 5 2 30 3 2 30 3 2 30 3 5 2 2 30 3 5 2 30 3 5 2 30 3 5 2 30 3 5 2 30 3 5 2 3 3 5 2 3 1 3 5 5 2 3 1 3 5 5 2 3 1 3 5 5 5 5 5 5 5 5 5 5 5 5 5	62 100 42 80 $1 (P = 0.81)^2 = 0.05)^2$ 216 200 30 216 30 322 20 100 80 478 478 478 400 478 80 478 316 20 80 316 20 476 80 476 80 478 80 500 700 700 700 700 700 700 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 70) 0.822) 1.08) 1.08) 1.08) 0); ² = 0 COTI <u>Events</u> 9 0 1 0 3 7 20 .82); ² = 20 7 4 .51); ² = .51); ² = 0 COTI <u>Events</u> 20 7 4 .51); ² = 0 .51); ² = .51); ³ = .51); ³ = .51); ³ = .51]; ³ = .51	SD SD 1.63 1.99 % Total 216 30 289 80 673 80 673 = 0% Total 216 20 80 316 = 0%	289 80 369 4.99 2.49 8.59 36.49 100.03 Weigh 66.19 19.49 14.49 100.03 Weigh 57.49	77.6% 22.4% 100.0% C C C C M.H 5 1.4 5 5.54 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.32 [-0.00, 0.6 0.00 [0.39, 2.57] Not estimable 19 [0.07, 19.88] 4 [0.25, 123.08] 0.60 [0.0, 9.36] 0.70 [0.21, 2.29] 0.11 [0.52, 1.93] 0.62 [0.16, 2.43] 0.49 [0.09, 2.74] .96 [0.56, 1.65] 0.0dds Ratio .4, Fixed, 95% CI .04 [0.56, 1.65] 0.04 [0.12, 7.440] 	7] 9] 5] 4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio M.H. Fixed, 95% CI 0.01 0.1 1 0 100 Favours TOETVA Favours COT Odds Ratio M.H. Fixed, 95% CI 0.01 0.1 1 0 100 Favours TEOTVA Favours COT
(G)	Sun 2020 Wang 2019 Total (95% CI) Heterogeneity: Chi ² : Test for overall effect Study or Subgroups Anuwong 2018 Kasemsiri 2020 Pe're2-Soto 2019 Sun 2020 Wang 2019 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effect Study or Subgroups Anuwong 2018 Pe're2-Soto 2019 Wang 2019 Total (95% CI) Total events Heterogeneity: Chi ² Test for overall effect	1.12 1. 1.48 2. = 0.06, df = 1 t Z = 1.94 (F TOET Events 9 0 1 2 1 5 * = 1.55, df = 1.55, df = ct: Z = 0.02 TOET Events 2 3 0 * = 1.36, df = ct: Z = 0.14 TOET	62 100 42 80 $1 (P = 0.81)^2 = 0.05)^2$ 216 200 30 216 30 322 20 100 80 478 478 478 400 478 80 478 316 20 80 316 20 476 80 476 80 478 80 500 700 700 700 700 700 700 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 700 800 70) 0.822) 1.08) 0.822) 1.08) 0.9) 1 0.07 1 0 3 3 7 20 3 3 7 20 3 3 7 20 0 3 3 7 20 0 3 3 7 20 0 3 3 7 20 0 3 3 7 20 0 0 3 3 7 20 0 0 1 1 5 0 1 1 5 0 1 1 8 20 1 20 1 20 1 20 1 20 1 20 1 2	<u>SD</u> 1.63 1.99 % <u>Total</u> 216 30 229 80 673 = 0% <u>Total</u> 20% 673 = 0%	289 80 369 4.99 2.49 8.59 36.49 100.03 Weigh 66.19 19.49 14.49 100.03 Weigh 57.49	77.6% 22.4% 100.0% C C C C M.H 5 1.4 5 5.54 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.32 [-0.00, 0.6 0.032 [-0.00, 0.6 0.039, 2.57] Not estimable 19 [0.07, 19.88] 0.86 [0.10, 9.36] 0.70 [0.21, 2.29] 0.17 [0.52, 1.93] 0.62 [0.16, 2.43] 0.62 [0.16, 2.43] 0.49 [0.09, 2.74] 96 [0.56, 1.65] 0.648 Ratio 1.75 [0.56, 1.65] 0.648 Ratio 1.49 [0.09, 2.74] 1.96 [0.56, 1.65] 0.648 Ratio 1.49 [0.56, 1.65] 	7] 9] 5] -4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio M.H. Fixed, 95% CI 0.01 0.1 1 10 100 Favours TOETVA Favours COT Odds Ratio M.H. Fixed, 95% CI 0.01 0.1 1 0 100 Favours TOETVA Favours COT Odds Ratio M.H. Fixed, 95% CI 0.01 0.1 1 0 100 Favours TEOTVA Favours COT Odds Ratio
(G)	Sun 2020 Wang 2019 Total (95% Cl) Heterogeneity: Chi ² : Test for overall effect Study or Subgroups Anuwong 2018 Kasemsiri 2020 Pe'rez-Soto 2019 Sun 2020 Wang 2019 Total (95% Cl) Total events Heterogeneity: Chi ⁷ Test for overall effe Study or Subgroups Heterogeneity: Chi ⁷ Total (95% Cl) Total events Heterogeneity: Chi ⁷ Test for overall effe Study or Subgroups	1.12 1. 1.48 2. = 0.06, df = 1 t Z = 1.94 (F TOET Events 0 1 2 1 5 1 8 = 1.55, df = 1 5 2 30 3 2 30 3 2 30 3 5 2 2 30 3 5 2 30 3 5 2 30 3 5 2 30 3 5 2 30 3 5 2 3 3 5 2 3 1 3 5 5 2 3 1 3 5 5 2 3 1 3 5 5 5 5 5 5 5 5 5 5 5 5 5	62 100 42 80 $1 (P = 0.81)^2 = 0.05$) VA Total 1 216 30 32 20 100 80 478 478 478 9 478 9 478 9 478 9 478 9 478 9 478 9 478 9 478 9 478 9 478 9 478 9 478 9 478 9 50 9 70 9 316 9 100 9 700 9 700 9 476 20 200 20 200 20 200 20 200 20 200 20 200 20) 0.822) 1.08) 1.08) 1.08) 0); ² = 0 COTI <u>Events</u> 9 0 1 0 3 7 20 .82); ² = 20 7 4 .51); ² = .51); ² = 0 COTI <u>Events</u> 20 7 4 .51); ² = 0 .51); ² = .51); ³ = .51); ³ = .51); ³ = .51]; ³ = .51	<u>SD</u> 1.63 1.63 216 300 289 80 673 = 0% 7 7 7 7 80 80 80 80 80 80 80 80 80 80 80 80 80	289 80 369 4.99 2.49 8.59 36.49 100.03 Weigh 66.19 19.49 14.49 100.03 Weigh 57.49	77.6% 22.4% 100.0% C t <u>M.H</u> 5 1.4 5 5.54 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0	 0.30 [-0.07, 0.6 0.40 [-0.29, 1.0 0.32 [-0.00, 0.6 0.32 [-0.00, 0.6 0.00 [0.39, 2.57] Not estimable 19 [0.07, 19.88] 4 [0.25, 123.08] 0.60 [0.0, 9.36] 0.70 [0.21, 2.29] 0.11 [0.52, 1.93] 0.62 [0.16, 2.43] 0.49 [0.09, 2.74] .96 [0.56, 1.65] 0.0dds Ratio .4, Fixed, 95% CI .04 [0.56, 1.65] 0.04 [0.12, 7.440] 	7] 9] 5] -4 -2 0 2 4 Favours TOETVA Favours COT Odds Ratio M.H. Fixed, 95% CI 0.01 0.1 1 10 100 Favours TOETVA Favours COT Odds Ratio M.H. Fixed, 95% CI 0.01 0.1 1 0 100 Favours TOETVA Favours COT Odds Ratio M.H. Fixed, 95% CI 0.01 0.1 1 0 100 Favours TEOTVA Favours COT Odds Ratio

Heterogeneity: Chi² = 0.51, df = 1 (P = 0.48); l² = 0%

Test for overall effect: Z = 1.93 (P = 0.05)

0.01 0.1 1 10 100 Favours TOETVA Favours COT FIGURE 2 A, Forest plots displaying operative time comparing TOETVA vs COT. B, Forest plots displaying blood loss comparing TOETVA vs COT. C, Forest plots displaying amount of drainage comparing TOETVA vs COT. D, Forest plots displaying number of retrieved central lymph node comparing TOETVA vs COT. E, Forest plots displaying number of metastatic central lymph nodes comparing TOETVA vs COT. F, Forest plots displaying transient RLN palsy comparing TOETVA vs COT. G, Forest plots displaying transient hypocalcaemia comparing TOETVA vs COT. H, Forest plots displaying hematoma comparing TOETVA vs COT. CI, confidence intervals; COT, conventional open thyroidectomy; RLN, transient recurrent laryngeal nerve; TOETVA, transoral endoscopic thyroidectomy vestibular approach [Color figure can be viewed at wileyonlinelibrary.com]




FIGURE 3 Funnel plot to investigate publication bias. OR, odds ratio [Color figure can be viewed at wileyonlinelibrary.com]

the safety and feasibility of the TOETVA for thyroid disease. These systematic reviews have reported that TOETVA was feasible and safe for the treatment of selected thyroid disease. However, controversy remains about whether TOETVA is appropriate for thyroid diseases, particularly for thyroid carcinoma.¹⁸ To the best of our knowledge, this is the first comprehensive metaanalysis aimed at comparing TOETVA vs COT for patients with thyroid lesions.

Based on our analysis, we found operating time was significantly longer in TOETVA group compared to COT group, which can be explained by the additional time for ports insertion and creation of working space.^{14,18,26} Operative time in TOETVA group may decrease with the increased endoscopic surgery training and experience.^{15,31} Wang et al¹⁸ demonstrated that TOETVA was associated with equivalent central lymph node dissection time as compared with that of COT. Our analysis also found that the amount of drainage in the TOETVA group was significantly greater than that in the COT group, which might be due to the requirement for larger subcutaneous flaps.¹⁸ Further analysis revealed no significant difference in intraoperative blood loss and postoperative hospital stay within the two groups.

With regard to the postoperative complications, our results revealed no significant difference in the incidence rates of transient RLN palsy, permanent RLN palsy, transient hypocalcemia, permanent hypocalcemia, and hematoma between the TOETVA and COT groups. This result might be attributed to the endoscopic magnification providing a better view of the RLN and parathyroid gland.^{18,19} In addition, intraoperative neuromonitoring for TOETVA can help prevent RLN injury by identifying RLN and confirming its integrity.³²

New specific complications brought by TOETVA include increased risk of wound infection and mental

-WILEY 351

nerve injury. Of the studies included in this analysis, three studies¹⁵⁻¹⁷reported wound infection and mental nerve injury. Concern for higher risk of wound infection occurred due to clean-contaminated procedure in TOETVA.³³ However, our results reveal no significant difference in the wound infection between the TOETVA and COT groups, possibly due to the prophylactic use of intravenous antibiotics and oral sterilization perioperatively for TOETVA.^{9,34} In terms of mental nerve injury introduced only by transoral vestibular approach TOETVA, Anuwong et al¹⁵ reported a 1.4% transient mental nerve injury incidence rate for TOETVA. Bian et al¹⁶ reported 17 patients experienced transient mental nerve injury. Pérez-Soto et al¹⁷ reported three patients presented transient mental nerve injury.

It is evident that that lymph node metastasis affected oncologic outcomes and was related to a higher patient mortality.^{35,36} Prophylactic ipsilateral central lymph node dissection was recommended for all papillary thyroid carcinoma patients based on the current Chinese guidelines. In our meta-analysis, three studies reported the number of retrieved central lymph node. The pooled data of retrieved central lymph node revealed no significant difference between TOETVA and COT group, which may indicate that the clearance of central lymph node is comparable within the two groups. Of the three studies included in this analysis, only one study¹⁸ demonstrated that TOETVA had equivocal number of positive central lymph nodes to COT.

The review has several limitations and hence the results should be interpreted cautiously. First, relatively small number of the studies with short-term follow-up data were included in the meta-analysis. Second, all the studies included were nonrandomized trials, which might over/under estimate the measured effect. Third, this study failed to analyze important outcomes including cosmetic results and oncological outcome due to lack of available data. Furthermore, some heterogeneity was observed in certain outcome measures. This might be explained by differences in patient selection, surgical procedure, and surgeons' experience. Therefore, welldesigned randomized controlled trials with emphasis on evaluating important outcomes and adequate follow-up are required to clarify ambiguities surrounding the use of TOETVA.

5 | CONCLUSIONS

This systematic review demonstrates that TOETVA is as feasible and safe as the COT for the treatment of patients with benign thyroid nodules and selected differential thyroid carcinomas, although TOETVA is not superior to conventional techniques with respect to operative time. Further larger randomized controlled trials with longer follow-up are still needed to confirm the clinical and oncological effectiveness of TOETVA.

ACKNOWLEDGMENT

LWILEY-

This work was supported by Sichuan Science and Technology Program (No. 2019YJ0038).

CONFLICT OF INTEREST

The authors declare no potential conflict of interest.

AUTHOR CONTRIBUTIONS

Tao Wei, Jingqiang Zhu, and Zhihui Li designed the research. Yichao Wang, Shengliang Zhou, and Shu Rui developed the literature search. Yichao Wang and Xueting Liu carried out statistical analysis of the studies. Yichao Wang drafted the article. All authors read and approved the final manuscript.

REFERENCES

- 1. Babin E, Sigston E, Hitier M, Dehesdin D, Marie JP, Choussy O. Quality of life in head and neck cancers patients: predictive factors, functional and psychosocial outcome. *Eur Arch Otorhinolaryngol.* 2008;265(3):265-270.
- Best AR, Shipchandler TZ, Cordes SR. Midcervical scar satisfaction in thyroidectomy patients. *Laryngoscope*. 2017;127(5): 1247-1252.
- Cai Q, Huang X, Han P, Sun W, Liang F, Jiang X. Endoscopyassisted thyroid surgery via a subclavian approach. *Surg Today*. 2013;43(5):479-484.
- Wang C, Feng Z, Li J, et al. Endoscopic thyroidectomy via areola approach: summary of 1,250 cases in a single institution. *Surg Endosc.* 2015;29(1):192-201.
- 5. Xie QP, Xiang C, Wang Y, et al. The patterns and treatment of postoperative hemorrhage and hematoma in total endoscopic thyroidectomy via breast approach: experience of 1932 cases. *Endocrine*. 2019;63(3):422-429.
- Kiriakopoulos A, Linos D. Gasless transaxillary robotic versus endoscopic thyroidectomy: exploring the frontiers of scarless thyroidectomy through a preliminary comparison study. *Surg Endosc.* 2012;26:2797-2801.
- Elzahaby IA, Fathi A, Abdelwahab K, et al. Endoscopic thyroidectomy using the unilateral axillo-breast approach versus the modified anterior chest wall approach: a prospective comparative study. *Surg Laparosc Endosc Percutan Tech.* 2018;28(6):366-370.
- Schardey HM, Barone M, Pörtl S, von Ahnen M, von Ahnen T, Schopf S. Invisible scar endoscopic dorsal approach thyroidectomy: a clinical feasibility study. *World J Surg.* 2010;34(12): 2997-3006.
- Wang Y, Zhang Z, Zhao Q, et al. Transoral endoscopic thyroid surgery via the tri-vestibular approach with a hybrid spacemaintaining method: a preliminary report. *Head Neck*. 2018;40 (8):1774-1779.
- 10. Anuwong A, Sasanakietkul T, Jitpratoom P, et al. Transoral endoscopic thyroidectomy vestibular approach (TOETVA):

indications, techniques and results. *Surg Endosc.* 2018;32(1): 456-465.

- 11. Dionigi G, Chai YJ, Tufano RP, Anuwong A, Kim HY. Transoral endoscopic thyroidectomy via a vestibular approach: why and how? *Endocrine*. 2018;59(2):275-279.
- 12. Tesseroli MAS, Spagnol M, Sanabria Á. Transoral endoscopic thyroidectomy by vestibular approach (TOETVA): initial experience in Brazil. *Rev Col Bras Cir.* 2018;45(5):e1951.
- Dionigi G, Bacuzzi A, Lavazza M, et al. Transoral endoscopic thyroidectomy: preliminary experience in Italy. *Updates Surg.* 2017;69(2):225-234.
- 14. Jitpratoom P, Ketwong K, Sasanakietkul T, Anuwong A. Transoral endoscopic thyroidectomy vestibular approach (TOETVA) for Graves' disease: a comparison of surgical results with open thyroidectomy. *Gland Surg.* 2016;5(6):546-552.
- 15. Anuwong A, Ketwong K, Jitpratoom P, Sasanakietkul T, Duh QY. Safety and outcomes of the transoral endoscopic thyroidectomy vestibular approach. *JAMA Surg.* 2018;153(1):21-27.
- Bian C, Liu H, Yao XY, et al. Complete endoscopic radical resection of thyroid cancer via an oral vestibule approach. *Oncol Lett.* 2018;16(5):5599-5606.
- Pérez-Soto RH, Ponce de León-Ballesteros G, Montalvo-Hernández J, et al. Transoral endoscopic thyroidectomy by vestibular approach-initial experience and comparative analysis in the first reported Mexican cohort. *J Laparoendosc Adv Surg Tech A*. 2019;29(12):1526-1531.
- Wang T, Wu Y, Xie Q, et al. Safety of central compartment neck dissection for transoral endoscopic thyroid surgery in papillary thyroid carcinoma. *Jpn J Clin Oncol.* 2020;50(4):387-391.
- 19. Sun H, Zheng H, Wang X, Zeng Q, Wang P, Wang Y. Comparison of transoral endoscopic thyroidectomy vestibular approach, total endoscopic thyroidectomy via areola approach, and conventional open thyroidectomy: a retrospective analysis of safety, trauma, and feasibility of central neck dissection in the treatment of papillary thyroid carcinoma. *Surg Endosc.* 2020;34 (1):268-274.
- Kasemsiri P, Trakulkajornsak S, Bamroong P, Mahawerawat K, Piromchai P, Ratanaanekchai T. Comparison of quality of life between patients undergoing trans-oral endoscopic thyroid surgery and conventional open surgery. *BMC Surg.* 2020;20(1):18.
- 21. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol*. 2010;25:603-605.
- 22. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol*. 2014;14:135.
- 23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557-560.
- Nakajo A, Arima H, Hirata M, et al. Trans-oral video-assisted neck surgery (TOVANS). A new transoral technique of endoscopic thyroidectomy with gasless premandible approach. *Surg Endosc.* 2013;27(4):1105-1110.
- 25. Wang C, Zhai H, Liu W, et al. Thyroidectomy: a novel endoscopic oral vestibular approach. *Surgery*. 2014;155(1):33-38.
- 26. Shan L, Liu JA. Systemic review of transoral thyroidectomy. Surg Laparosc Endosc Percutan Tech. 2018;28(3):135-138.
- Camenzuli C, Schembri Wismayer P, Calleja Agius J. Transoral endoscopic thyroidectomy: a systematic review of the practice so far. *JSLS*. 2018;22(3):e2018.00026.

352

- Tartaglia F, Maturo A, Di Matteo FM, et al. Transoral video assisted thyroidectomy: a systematic review. *G Chir.* 2018;39(5): 276-283.
- Chen S, Zhao M, Qiu J. Transoral vestibule approach for thyroid disease: a systematic review. *Eur Arch Otorhinolaryngol.* 2019;276(2):297-304.
- Fernandez-Ranvier G, Meknat A, Guevara DE, Inabnet WB 3rd. Transoral endoscopic thyroidectomy vestibular approach. *JSLS* 2019;23(4):e2019.00036.
- 31. Russell JO, Clark J, Noureldine SI, et al. Transoral thyroidectomy and parathyroidectomy—a North American series of robotic and endoscopic transoral approaches to the central neck. *Oral Oncol.* 2017;71:75-80.
- Wang Y, Yu X, Wang P, et al. Implementation of intraoperative neuromonitoring for transoral endoscopic thyroid surgery: a preliminary report. J Laparoendosc Adv Surg Tech A. 2016;26(12):965-971.
- Anuwong A. Transoral endoscopic thyroidectomy vestibular approach: a series of the first 60 human cases. *World J Surg.* 2016;40(3):491-497.

- Chai YJ, Chung JK, Anuwong A, et al. Transoral endoscopic thyroidectomy for papillary thyroid microcarcinoma: initial experience of a single surgeon. *Ann Surg Treat Res.* 2017;93(2):70-75.
- 35. Bhattacharyya N. Surgical treatment of cervical nodal metastases in patients with papillary thyroid carcinoma. *Arch Otolaryngol Head Neck Surg*. 2003;129(10):1101-1104.
- Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. *Cancer*. 2006; 106(3):524-531.

How to cite this article: Wang Y, Zhou S, Liu X, et al. Transoral endoscopic thyroidectomy vestibular approach vs conventional open thyroidectomy: Meta-analysis. *Head & Neck*. 2021; 43:345–353. <u>https://doi.org/10.1002/hed.26486</u>